Table 5.
Value assessment index system.
| Domains | Subdomains | Indicators | Combination weight |
|---|---|---|---|
| Disease burden | Individual burden | Abor impairment extent | 0.85 |
| Personal psychological burden | 0.78 | ||
| Social activities extent | 0.66 | ||
| Family burden | Proportion of family expenses for illness | 1.08 | |
| Family members’ psychological burden | 0.88 | ||
| Social burden | Personal productivity affection on socio-economic | 1.36 | |
| Therapeutic value | Benefit value | The necessity of off-label use for drugs | 1.43 |
| Standard regimen available as control | 1.54 | ||
| Hazard ratio | 1.45 | ||
| Overall survival rate | 1.50 | ||
| Overall survival | 1.50 | ||
| Progression-free survival rate | 1.51 | ||
| Progression-free survival | 1.49 | ||
| overall response rate | 1.51 | ||
| Adverse reaction | Adverse reaction grading | 3.58 | |
| Adverse reaction incidence | 3.33 | ||
| Duration of adverse reactions | 3.14 | ||
| Survival value | Treatment-free interval | 4.44 | |
| Quality of life | 4.44 | ||
| Symptoms remission with patients reported | 4.22 | ||
| Economic affection | Treatment cost per course | 2.56 | |
| Proportion of patients’ out-of-pocket expenses (total course) | 2.59 | ||
| Other forms of cost compensation | 1.88 | ||
| Drug novelty | Innovation value | Innovation international | 2.18 |
| Innovation in China | 2.14 | ||
| Alternative | Affordable access for drugs (generic drugs or quality consistency evaluation of generic drugs) | 2.27 | |
| Therapeutic regimen alternative | 2.35 | ||
| evidence source and type | Secondary studies | Clinical practice guideline | 2.05 |
| Cochrane systematic review | 1.95 | ||
| Other systematic reviews (including Meta-analysis) | 1.78 | ||
| Clinical trials | Randomized controlled trial (phase III) | 3.51 | |
| Randomized controlled trial (phase II) | 3.53 | ||
| Real world research | Cohort study | 0.80 | |
| Case-control study | 0.79 | ||
| Case series | 0.74 | ||
| Case report | 0.71 | ||
| others | Expert consensus | 0.33 | |
| Multidisciplinary collaboration | 0.32 | ||
| Evidence submitted by pharmaceutical manufacturers | 0.28 | ||
| Grading of evidence recommendation | Evidence evaluation methods/tools | Evidence recommendation | 1.72 |
| Quality grading of evidence | 1.71 | ||
| Evidence evaluation objective | Validity | 1.12 | |
| Applicability | 1.12 | ||
| Clinical importance | 1.21 | ||
| Consistency of evidence results | Consistency | Consistent results reported from at least two same type of study as evidence | 1.52 |
| Single report as evidence | 1.37 | ||
| Update/correction | New types of evidence | 1.47 | |
| Evidence updated | 1.42 | ||
| Value composition/integration | Weight of results | Weight for indicators | 0.70 |
| Weight for evidence type | 0.65 | ||
| Weight for evidence grading | 0.68 | ||
| Results forms | Synthesis of evidence results | 2.25 | |
| Public feedback/comments | Public feedback mechanism | Issued by association | 2.84 |
| Issued by hospitals and its alliance | 2.53 | ||
| Frequency of public feedback | Issued regularly | 2.16 | |
| Issued irregularly, as evidence updated | 2.08 |